初级膜增殖性结膜膜炎:自然史,病原和治疗方法
Edward J Filippone1, John L Farber2
1Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, United States.
Frontiers in nephrology
|March 2, 2026
概括
原发性膜增殖性球膜炎 (MPGN) 是一种罕见的病,通常涉及补体调节失调. 补充抑制疗法,如伊普塔科潘和佩格塞塔科普兰,现在是MPGN的关键治疗方法,改善了患者的治疗结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 补充系统 补充系统
背景情况:
- 原发性膜增殖性结膜炎 (MPGN) 是一种超罕见的病,被归类为免疫复杂介导 (IC-MPGN) 或C3结膜病 (C3),包括C3结膜炎 (C3GN) 和密集沉积病 (DDD).
- 区分MPGN亚型依赖于免疫光和电子显微镜,C3染色是区分它们与其他MPGN原因的共同特征.
- MPGN呈现的变化很大,从尿路异常到脏综合征或快速进展,预后不佳,功能衰竭和移植后复发率高.
研究的目的:
- 审查原发性MPGN的分类,发病,临床表现和治疗策略.
- 突出MPGN发病过程中补充替代途径失调的核心作用.
- 讨论新兴的治疗领域,重点是补充抑制剂.
主要方法:
- 关于初级MPGN的文献综述,重点关注分类,诊断标准和病变发生.
- 对临床表现,预后因素和结果的分析,包括移植后复发.
- 评估当前和新兴的治疗方法,包括支持性护理,免疫抑制和向补充抑制.
主要成果:
- 主要MPGN病原发生与补充替代途径失调有关,多达80%的病例是由突变或自身抗体驱动的.
- 在20-40%的MPGN患者中发现了偏蛋白质,可能有助于补充失调.
- 两种补充抑制剂,伊普塔科潘 (B因子抑制剂) 和佩格塞塔科普兰 (C3抑制剂),分别被FDA批准用于C3G和IC-MPGN.
结论:
- 主要MPGN是一种严重的疾病,预后不好,通常涉及补体系统调节失调.
- 补充抑制疗法代表了MPGN治疗的重大进步,为C3G和IC-MPGN提供了有针对性的方法.
- 治疗需要排除次要原因,支持性护理,并考虑补充抑制剂作为一线治疗,并对移植后的复发进行警监测.
关键词:
在C3型血球膜炎中.在C3型淋巴细胞病变中.另一个路径是交替路径.互补系统是互补的系统.密集沉积病的疾病.这就是伊普塔科潘 (Iptacopan).这是一种膜增殖性球性炎 (glomerulonephritis).佩格塞塔科普兰是指一个平面.更多相关视频
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.6K
06:39Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
Published on: August 19, 2020
6.2K
相关概念视频
01:29Acute Kidney Injury II: Pathophysiology
1.4K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.4K
01:24Nephrotic Syndrome I : Introduction
778
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
778
01:29Acute Kidney Injury III: Clinical Manifestations
1.1K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.1K
01:27Acute Pyelonephritis I: Introduction
885
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
885
01:24Nephrotic Syndrome III : Nursing Management
400
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
400
01:28Chronic Kidney Disease III: Interprofessional Care
539
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
539